TI
SGMT icon

Trexquant Investment’s Sagimet Biosciences SGMT Stock Holding History

Trexquant Investment’s Portfolio SGMT Stock Details SGMT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-26,132
Closed -$85.2K – 1837
2025
Q1 		$85.2K Buy
+26,132
New +$110K ﹤0.01% 1505

Other funds holding SGMT

WP
Woodline Partners San Francisco, California $26.4B AUM 44.85% 1-Year Est. Return
BOCH
Blue Owl Capital Holdings New York $372M AUM 78.25% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
HA
HHLR Advisors Grand Cayman, Cayman Islands $1.67B AUM 7.53% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $3.61B AUM 203.3% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
BCM
Bridgeway Capital Management Houston, Texas $4.97B AUM 44.96% 1-Year Est. Return
RAM
Readystate Asset Management Chicago, Illinois $2.23B AUM 15% 1-Year Est. Return

Trexquant Investment's SGMT Position: Q2 2025 in Review

Trexquant Investment sold out of Sagimet Biosciences (SGMT) in Q2 2025, closing a stake of 26,132 shares — an estimated $85.2K sold.

Trexquant Investment first reported a position in SGMT in Q1 2025 and held it in 1 quarter. The position peaked at $85.2K in Q1 2025. 67 funds tracked by Wall St. Rank hold SGMT as of Q2 2025.

  • Trexquant Investment reported no remaining Sagimet Biosciences position as of Q2 2025 after selling out during the quarter.
  • Trexquant Investment sold 26,132 Sagimet Biosciences shares in Q2 2025, an estimated $85.2K.
  • Trexquant Investment first reported a position in Sagimet Biosciences in Q1 2025 and held it in 1 quarter.
  • Trexquant Investment's Sagimet Biosciences position peaked at $85.2K in Q1 2025.
  • 67 funds tracked by Wall St. Rank held Sagimet Biosciences as of Q2 2025.

Based on Trexquant Investment's 13F filing for Q2 2025, filed 12 Aug 2025.